Sign in to view content

Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study

Nancy M. Holekamp, MD, FASRS

Video
Published 2021

Related

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of GA: A Post Hoc Analysis of OAKS, DERBY, and FILLY
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2022
Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Annual Meeting Talks
2024

Category: AMD-Non-Neovascular

See more